NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Becton Dickinson & Co. BDX
19 fiscal years on record · USD · FY2025 reported · SEC filings only
12 YEARS OF DIVIDEND GROWTH
In brief
What this company does
Written from the business description in BECTON DICKINSON & CO's annual report to the U.S. Securities and Exchange Commission, filed 25 November 2025. Every sentence was checked against that document before publication.
Growth
USD 21.8B
Revenue, FY2025 · full 19-year series below
Revenue $B
Net income $B
FY2025 · Revenue 21.8 · Net income 1.7
Compound annual growth
+5.0%
+6.3%
+7.8%
+7.8%
−1.9%
+13.9%
+9.2%
−0.3%
+16.5%
+5.7%
+0.4%
+6.1%
+5.7%
+5.7%
+7.1%
+11.6%
+16.4%
+16.3%
+5.2%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +6.3% a year over five years — but profit grew faster: net income at +13.9%, earnings per share at +16.5%.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
8 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 11.8% · Net 7.7%
ROE
FY2025 · ROE 6.5%
Each USD of equity produced 7 cents of profit this year.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 21.8 | 20.2 | 19.4 | 18.9 | 19.1 | 16.1 | 17.3 | 16.0 | 12.1 | 12.5 | 10.3 | 8.4 | 8.1 | 7.7 | 7.6 | 7.1 | 7.0 | 6.9 | 6.3 |
| Operating income $B | 2.6 | 2.4 | 2.1 | 2.3 | 2.2 | 0.9 | 1.8 | 1.5 | 1.5 | 1.4 | 1.1 | 1.6 | 1.3 | 1.6 | 1.7 | 1.6 | 1.6 | 1.5 | 1.2 |
| EBITDA $B | 5.0 | 4.7 | 4.4 | 4.5 | 4.5 | 3.0 | 4.0 | 3.5 | 2.6 | 2.5 | 2.0 | 2.2 | 1.8 | 2.1 | 2.2 | 2.1 | 2.1 | 2.0 | 1.6 |
| Income tax $B | 0.2 | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | −0.1 | 0.9 | −0.1 | 0.1 | 0.0 | 0.3 | 0.2 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.3 |
| Net income $B | 1.7 | 1.7 | 1.5 | 1.8 | 2.1 | 0.9 | 1.2 | 0.3 | 1.1 | 1.0 | 0.7 | 1.2 | 1.3 | 1.2 | 1.3 | 1.3 | 1.2 | 1.1 | 0.9 |
| Free cash flow $B | 2.7 | 3.1 | 2.1 | 1.5 | 2.9 | 2.2 | 2.4 | 2.0 | 1.8 | 1.9 | 1.1 | 1.2 | 1.2 | 1.2 | 1.1 | 1.1 | 1.1 | 1.0 | 0.7 |
| EPS, diluted $ | 5.82 | 5.86 | 4.94 | 5.88 | 6.85 | 2.71 | 3.94 | 0.60 | 4.60 | 4.49 | 3.35 | 5.99 | 6.49 | 5.59 | 5.62 | 5.49 | 4.99 | 4.46 | 3.49 |
| Dividend / sh $ | 4.16 | 3.80 | 3.64 | 3.48 | 3.32 | 3.16 | 3.08 | 3.00 | 2.92 | 2.64 | 2.40 | 2.18 | 1.98 | · | · | 1.48 | 1.32 | 1.14 | · |
| Payout % | 71 | 65 | 75 | 61 | 50 | 117 | 80 | 298 | 62 | 58 | 70 | 36 | 30 | 31 | 28 | 26 | 26 | 25 | 27 |
| ROE % | 6.5 | 6.6 | 5.8 | 7.3 | 8.8 | 3.9 | 5.9 | 1.8 | 10.7 | 13.2 | 11.4 | 23.5 | 28.2 | 26.1 | 24.8 | 24.9 | 24.4 | 22.8 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Compare
This company against its peers
Becton Dickinson & Co.vsThermo Fisher Scientific Inc.Same industry: Surgical & Medical Instruments & ApparatusBecton Dickinson & Co.vsNorthrop Grumman Corp.Same industry: Surgical & Medical Instruments & ApparatusBecton Dickinson & Co.vsMedtronic PLCSame industry: Surgical & Medical Instruments & ApparatusBecton Dickinson & Co.vsStryker Corp.Same industry: Surgical & Medical Instruments & ApparatusBecton Dickinson & Co.vs3M Co.Same industry: Surgical & Medical Instruments & ApparatusBecton Dickinson & Co.vsDanaher Corp.Same industry: Surgical & Medical Instruments & ApparatusBecton Dickinson & Co.vsTrane Technologies PLCSame industry: Surgical & Medical Instruments & Apparatus
Provenance
Company facts, as filed
How we verify · 0 failures in 80 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 3 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNYSE
Incorporated inNew Jersey
Fiscal year endsSeptember 30
Data on record since2007